April 2026 Research Update

This month added a clearer picture that IgG4-related disease can leave lasting organ damage over time, and that people with a relapsing course may be more likely to accumulate damage. In a single-center group of patients followed for years, damage was already common at diagnosis and became more frequent at later follow-ups. The same study also reported that higher damage scores at the last follow-up tracked with a higher risk of death during follow-up, showing why damage (not only active inflammation) is an important part of the illness story. [1]

In this cohort, damage was measured with a structured scoring tool (a damage index) at diagnosis and again over time, rather than relying only on symptoms or lab tests. A relapsing pattern of disease was linked with higher damage at the last visit, and deaths occurred during the follow-up period, with some attributed to IgG4-RD or its treatment in the report. This helps connect day-to-day disease control with the longer-term idea of preventing irreversible changes, even though the study does not explain which specific treatments best reduce damage. [1]

For patients and caregivers, this study mainly adds understanding about what can happen over the long run: damage can be present early and can build up over time, especially when the disease keeps coming back. It does not tell an individual person what will happen to them, but it supports the idea that tracking damage separately from flare activity matters in research and follow-up discussions. What remains uncertain from this single-center retrospective work is how well these findings apply to different populations and which approaches most strongly change damage risk. [1]

Several papers this month showed that IgG4-related disease can closely resemble other conditions, and that diagnosis often depends on putting biopsy results together with imaging and blood or spinal fluid tests. Across reports, IgG4-RD sometimes appeared in unusual places or in ways that looked like cancer, lymphoma, or other immune diseases, and sometimes other diseases produced IgG4-like features. The shared message is that a single clue (like an imaging appearance or even a blood IgG4 level) may not be enough on its own, and some cases required repeat or more targeted tissue testing to reach a clearer answer. [2] [3] [4]

One imaging study suggested a specific clue for IgG4-related disease around the eye: infraorbital nerve measurements were thicker than in matched controls, and bilateral enlargement, when present, was highlighted as a possible radiologic clue. This does not diagnose IgG4-RD by itself, because nerve enlargement was also seen in benign and malignant causes, but it provides a more concrete imaging pattern that may raise suspicion for IgG4-related ophthalmic disease when the clinical picture fits. The study focused on non-traumatic nerve involvement and compared measurements across different causes. [5]

Multiple reports centered on conditions that can be mistaken for IgG4-RD or that can overlap in appearance. A man with pancreatitis, retroperitoneal fibrosis, and lymph node enlargement was ultimately diagnosed with idiopathic multicentric Castleman disease based on biopsy, with normal IgG4 levels and no IgG4-positive cells reported, and he improved with siltuximab. Another paper combined a case report with a review suggesting the IgG4/IgG ratio in multicentric Castleman disease is generally much lower than what is typically seen in IgG4-RD, although rare exceptions were noted. [4] [6]

Other case reports showed how IgG4-RD can mimic cancer or other immune disorders, sometimes even when blood IgG4 levels are normal. A biliary stricture that looked like cholangiocarcinoma on imaging was diagnosed as IgG4-related sclerosing cholangitis only after surgery and tissue review, followed by improvement after corticosteroids. Another report described possible IgG4-related hypertrophic pachymeningitis alongside anti-NMDAR disease, supported by dura biopsy and spinal fluid testing, but also highlighted diagnostic uncertainty and relapse. [2] [7]

Some reports emphasized that tissue testing can help avoid mislabeling a different disease as IgG4-RD. A breast inflammatory myofibroblastic tumor created a biopsy and cytology pitfall, and further immunostaining helped distinguish it from IgG4-related disease. A separate report described Erdheim-Chester disease where one lesion had an IgG4-rich pattern but another lesion and a MAP2K1 mutation supported Erdheim-Chester disease, with a strong response to trametinib. [8] [9]

For patients, these studies mainly matter because they explain why IgG4-RD can take time to diagnose and why doctors may request a biopsy, repeat biopsy, or extra lab testing when the first answer is unclear. The imaging work on infraorbital nerve thickening may matter in the future as a supportive clue for IgG4-related eye disease, but it is not a stand-alone test. What remains uncertain is how often these specific look-alike situations occur in the broader IgG4-RD community, since much of this month is based on individual cases and small series. [5] [2]

This month included many case reports showing that IgG4-related disease can affect a wide range of organs, sometimes in uncommon locations, and that improvement was often reported after anti-inflammatory or immune-targeting treatments. Several cases described symptom improvement after corticosteroids, and a few included additional medicines or surgery depending on the organ involved. Because these are individual cases, they cannot show how often these presentations happen or which treatment works best for most people, but they expand the list of real-world ways IgG4-RD may appear. [10] [11] [3] [12] [13]

Some reports highlighted rare or easily misunderstood locations. A 29-year-old man had IgG4-RD presenting as a penile mass that shrank markedly with prednisone and did not recur during follow-up in the report. A 51-year-old woman had IgG4-RD involving the uterus and abdominopelvic lymph nodes, with a substantial drop in serum IgG4 after postoperative therapy that included dexamethasone, cyclophosphamide, and bortezomib. [10] [11]

Several cases involved the head and neck, including the eyes and sinuses. A 74-year-old man had posterior uveitis that initially mimicked intraocular lymphoma, with IgG4-RD confirmed on repeat biopsy and improvement reported with prednisone and rituximab. A 64-year-old man had IgG4-related rhinosinusitis with prominent eosinophilia and very high serum IgG4, suggesting that eosinophilia can occur in IgG4-RD and may complicate the diagnostic picture. [3] [14]

Two reports focused on xanthogranulomatous disease around the eye and how it can have variable IgG4 features. A small series of adult orbital xanthogranulomatous disease cases found variable increases in IgG4-positive cells, and under modern criteria the authors noted that true systemic IgG4-RD coexistence appeared less common than older reports suggested. A separate case of AAPOX (a type of orbital xanthogranulomatous disease), with signs of an IgG4 association such as increased IgG4-positive cells, described swelling and ptosis that improved after a combination approach that included local steroids, short-term systemic corticosteroids, and methotrexate. [15] [16]

Other cases showed that IgG4-RD can involve the liver and pancreas, and even bones, in ways that can cause serious symptoms. An elderly man with IgG4-related autoimmune hepatitis and concurrent pancreatitis improved with prednisone, with liver blood tests normalizing by about 8 weeks in the report. Another report described destructive bone changes at the top of the spine with major weakness, where surgery plus rehabilitation led to substantial recovery, and tissue testing confirmed IgG4-RD. [12] [13]

For patients and caregivers, these cases mainly add recognition: IgG4-RD can show up in unexpected places, and it may look like cancer, infection, or other immune diseases until tissue testing clarifies what it is. The reports also show that improvement is possible, including after corticosteroids in several different organ situations, but single-patient reports cannot predict how someone else will respond. What remains uncertain is how common these specific presentations are and how outcomes compare across different treatment choices, since the evidence here is mostly case-based. [12] [10]

One laboratory-based patient study this month linked IgG4-related disease to changes in how certain B cells handle fats and other small molecules, offering a possible biological fingerprint of the disease. Compared with healthy controls, B cells from people with IgG4-RD showed many metabolite differences, and the researchers reported a 14-metabolite panel that separated IgG4-RD from controls with high accuracy in their dataset. The work also found higher lipid content in B cells, with plasmablasts and plasma cells showing the highest lipid content and fatty acid synthase expression, and noted metabolic differences between fibrotic and inflammatory subgroups. [17]

The study also reported that certain metabolites tracked with blood antibody levels, including one that correlated with IgG4 and another that correlated with IgE in the analysis. This kind of result does not yet explain symptoms directly, but it supports the idea that IgG4-RD is not only about where inflammation occurs, but also about how immune cells are functioning at a basic level. The findings are an early step toward future biomarkers, although the report does not state that these tests are ready for routine care. [17]

For patients, this is mainly early research that adds to understanding rather than changing diagnosis or treatment now. It helps clarify that B cells in IgG4-RD may behave differently in ways that could someday support blood-based testing or more tailored research approaches. What remains uncertain is whether these metabolic patterns predict disease activity, organ involvement, or treatment response in real-world care, since this work compared patients with healthy controls and did not test clinical outcomes. [17]